The majority of pharmacological agents currently approved for acute MI treatment are small molecules targeting three primary mechanisms: (1) thrombosis and blood clot prevention (antithrombotic/antiplatelets, for example, P2Y12 receptor antagonist, PAR-1 inhibitor), (2) cardiovascular remodeling and hemodynamic control (neurohormonal modulators, for example, angiotensin II/aldosterone receptor blockers) and (3) metabolic and lipid regulation (metabolic protectors, for example, PCSK9 inhibitors, SGLT2 inhibitors)213. Here, SLC5A2 is linked to myocardial infarction.